Clinical and experimental studies on adenine, various nucleosides and their analogs in hematology.
In red blood cells as well as in platelets there appears to be a decrease in adenine nucleotides during storage under blood bank conditions. This can be decreased by use of anticoagulant preservatives with higher phosphate content than the standard ACD solution, through the addition of adenine and inosine. Maintenance of higher ATP levels appears to be related to longer circulating life span after transfusion into patients in the case of red blood cells but not platelets. Inosine and more alkaline preservative medium also contribute to the maintenance of 2,3-DPG levels in red blood cells, and with it to the maintenance of normal hemoglobin dissociation curves and thus oxygen-carrying capacity. Certain nucleoside analogs may contribute to the preservation of platelets and of whole blood by their platelet-aggregation inhibitory activity. Platelet-aggregation inhibitors may also be useful in preventing thromboembolic episodes with potentially greater safety than anticoagulants.
D000225:Adenine / Q000097:blood* / Q000494:pharmacology; D000328:Adult; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000378:metabolism*; D002951:Citrates; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D005341:Fibrinolysin / Q000378:metabolism; D005947:Glucose; D006801:Humans; D007288:Inosine / Q000494:pharmacology; D007773:Lactates / Q000097:blood; D008297:Male; D009705:Nucleosides / Q000097:blood*; D010042:Ouabain / Q000494:pharmacology; D010100:Oxygen / Q000097:blood; D010710:Phosphates; D011188:Potassium / Q000097:blood; D012265:Ribonucleotides / Q000096:biosynthesis; D013329:Structure-Activity Relationship; D013997:Time Factors; D014529:Uridine / Q000494:pharmacology
D002951:Citrates; D007773:Lactates; D009705:Nucleosides; D010710:Phosphates; D012265:Ribonucleotides; D007288:Inosine; D010042:Ouabain; D005341:Fibrinolysin; D005947:Glucose; D000225:Adenine; D011188:Potassium; D010100:Oxygen; D014529:Uridine